Related to Transgene and Vivalis to Evaluate MVA Vaccine Production in EB66 Duck Stem Cell Line

• GSK’s Seasonal Flu Vaccine Green-Lighted for Use in Children
  
• Alnara Selects Lonza for Commercial Manufacture of Pancreatic Insufficiency Therapy
  
• Lonza Takes Equity Stake in Ciliate-Expression System Company
  
• ArmaGen Chooses PacificGMP to Manufacture Fusion Protein for Phase I Trial in Stroke and Parkinson’s
  
• Novartis to Buy 85% of Chinese Vaccines Company for $125M
  
• NIAID Commissions GenVec for HIV and Influenza Vaccine Development for $2.6M
  
• ProMetic to Provide Halozyme with Synthetic Ligand Affinity Adsorbent
  
• Talecris Pours $268.7M into Production Plant in North Carolina
  
• Novartis’ Swine Flu Vaccine Effective at Half the Current Antigen Dose
  
• Novartis Inaugurates $1B U.S. Cell Culture Flu Vaccine Facility
  
• BioLife to Produce Custom Biopreservation Media for Centocor
  
• Cancer Research UK to Conduct Phase I Trial with Merck KGaA’s B-Cell Lymphoma Candidate
  
• ProMetic and Abraxis Team Up to Develop New Applications of Prion-Capture Platform
  
• BioMimetic Strengthens Arrangement with Novartis for Exclusive Supply of Recombinant Human Platelet-Derived Growth Factor
  
• TAP and Centre for Innovative Manufacturing in Regenerative Medicine Ink Five-Year Extension
  
• MorphoSys Expands Deal Leveraging Wacker’s Bacterial Secretion Technology
  
• Progenitor Cell Therapy Completes First Stage of Production Plant
  
• Lonza Launches Cells on Demand Services for Cell Culture and Transfection
  
• Lonza to Manufacture Micromet’s Blinatumomab BiTE Antibody
  
• Formatech to Fill and Finish One Lot of ViroMed’s Preclinical Cancer Vaccine at No Charge